Investigators have identified and validated the peak early-phase enhancement ratio (PEER) radiographic measurement for accurately differentiating CD117+ renal oncocytoma from CD117+ chromophobe renal cell carcinoma (RCC). Retrospective analysis revealed the most reliable variable for tumour differentiation was the tumor:cortex PEER using multiphase CT. In prospective validation, PEER had 100% accuracy in differentiating tumours.
References
Original article
Amin, J. et al. Identification and validation of radiographic enhancement for reliable differentiation of CD117( + ) benign renal oncocytoma and chromophobe renal cell carcinoma. Clin. Cancer Res. https://doi.org/10.1158/1078-0432.CCR-18-0252 (2018)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Stone, L. PEERfect scores for RCC. Nat Rev Urol 15, 656 (2018). https://doi.org/10.1038/s41585-018-0069-y
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41585-018-0069-y